(HUN) Huntsman - NYSE
Sector: Basic Materials | Industry: Chemicals | Exchange: NYSE (USA) | Market Cap: 2.644m USD | Total Return: 51% in 12m
Avg Turnover: 56.8M
Qual. Beats: 0
Rev. Trend: -86.1%
Qual. Beats: 1
Warnings
High Debt/EBITDA (20.6) with thin interest coverage (-2.1)
Interest Coverage Ratio -2.1 is critical
Tailwinds
Confidence
Huntsman Corporation (NYSE: HUN) is a global manufacturer of organic chemical products, operating through three primary segments: Polyurethanes, Performance Products, and Advanced Materials. Headquartered in The Woodlands, Texas, the company serves diverse end-markets including aerospace, automotive, construction, and electronics. Its portfolio focuses on specialized chemistries such as MDI, amines, and epoxy resins used in high-performance applications like insulation and carbon nanomaterials.
The company operates within the diversified chemicals sector, which is characterized by high capital intensity and sensitivity to raw material costs, particularly benzene and natural gas. Huntsman’s business model emphasizes downstream integration, moving from basic commodity chemicals toward value-added specialty formulations that offer higher margins and greater technical differentiation. This transition helps mitigate the cyclicality typically associated with primary chemical production.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data on ValueRay.
- MDI and polyurethane spreads drive core earnings volatility and margins
- Global construction and automotive demand cycles dictate volume growth trajectories
- Raw material costs for benzene and propylene impact operational profitability
- Aerospace and electronics recovery supports high-margin advanced materials segment growth
- Energy price fluctuations in European manufacturing hubs affect production competitiveness
| Net Income: -324.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.84 > 1.0 |
| NWC/Revenue: 5.46% < 20% (prev 12.48%; Δ -7.02% < -1%) |
| CFO/TA 0.04 > 3% & CFO 310.0m > Net Income -324.0m |
| Net Debt (2.55b) to EBITDA (124.0m): 20.56 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (173.0m) vs 12m ago 0.35% < -2% |
| Gross Margin: 12.88% > 18% (prev 14.49%; Δ -1.62% > 0.5%) |
| Asset Turnover: 79.27% > 50% (prev 82.63%; Δ -3.36% > 0%) |
| Interest Coverage Ratio: -2.06 > 6 (EBIT TTM -167.0m / Interest Expense TTM 81.0m) |
| A: 0.04 (Total Current Assets 2.03b - Total Current Liabilities 1.72b) / Total Assets 7.13b |
| B: 0.24 (Retained Earnings 1.74b / Total Assets 7.13b) |
| C: -0.02 (EBIT TTM -167.0m / Avg Total Assets 7.18b) |
| D: 0.63 (Book Value of Equity 2.68b / Total Liabilities 4.23b) |
| Altman-Z'' = 1.59 = BB |
| DSRI: 1.02 (Receivables 776.0m/797.0m, Revenue 5.69b/5.98b) |
| GMI: 1.13 (GM 14.49% / 12.88%) |
| AQI: 1.30 (AQ_t 0.37 / AQ_t-1 0.29) |
| SGI: 0.95 (Revenue 5.69b / 5.98b) |
| TATA: -0.09 (NI -324.0m - CFO 310.0m) / TA 7.13b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of June 15, 2026, the stock is trading at USD 15.74 with a total of 2,945,667 shares traded.
Over the past week, the price has changed by +10.77%,
over one month by +9.99%,
over three months by +33.39% and
over the past year by +51.02%.
Huntsman has received a consensus analysts rating of 3.13. Therefore, it is recommended to hold HUN.
- StrongBuy: 1
- Buy: 1
- Hold: 12
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 14.3 | -9.1% |
P/E Forward = 153.8462
P/S = 0.4645
P/B = 0.9863
P/EG = 2.2202
Revenue TTM = 5.69b USD
EBIT TTM = -167.0m USD
EBITDA TTM = 124.0m USD
Long Term Debt = 1.68b USD (from longTermDebt, last quarter)
Short Term Debt = 433.0m USD (from shortTermDebt, last quarter)
Debt = 2.92b USD (from shortLongTermDebtTotal, last quarter) + Leases 431.0m
Net Debt = 2.55b USD (calculated: Debt 2.92b - CCE 369.0m)
Enterprise Value = 5.19b USD (2.64b + Debt 2.92b - CCE 369.0m)
Interest Coverage Ratio = -2.06 (Ebit TTM -167.0m / Interest Expense TTM 81.0m)
EV/FCF = 38.47x (Enterprise Value 5.19b / FCF TTM 135.0m)
FCF Yield = 2.60% (FCF TTM 135.0m / Enterprise Value 5.19b)
FCF Margin = 2.37% (FCF TTM 135.0m / Revenue TTM 5.69b)
Net Margin = -5.69% (Net Income TTM -324.0m / Revenue TTM 5.69b)
Gross Margin = 12.88% ((Revenue TTM 5.69b - Cost of Revenue TTM 4.96b) / Revenue TTM)
Gross Margin QoQ = 12.89% (prev 12.10%)
Tobins Q-Ratio = 0.73 (Enterprise Value 5.19b / Total Assets 7.13b)
Interest Expense / Debt = 2.78% (Interest Expense 81.0m / Debt 2.92b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -131.9m (EBIT -167.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.18 (Total Current Assets 2.03b / Total Current Liabilities 1.72b)
Debt / Equity = 1.09 (Debt 2.92b / totalStockholderEquity, last quarter 2.68b)
Debt / EBITDA = 20.56 (Net Debt 2.55b / EBITDA 124.0m)
Debt / FCF = 18.88 (Net Debt 2.55b / FCF TTM 135.0m)
Total Stockholder Equity = 2.76b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.51% (Net Income -324.0m / Total Assets 7.13b)
RoE = -11.76% (Net Income TTM -324.0m / Total Stockholder Equity 2.76b)
RoCE = -3.76% (EBIT -167.0m / Capital Employed (Equity 2.76b + L.T.Debt 1.68b))
RoIC = -2.37% (negative operating profit) (NOPAT -131.9m / Invested Capital 5.56b)
WACC = 6.38% (E(2.64b)/V(5.56b) * Re(11.01%) + D(2.92b)/V(5.56b) * Rd(2.78%) * (1-Tc(0.21)))
Discount Rate = 11.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.47 | Cagr: 0.26%
[DCF] Terminal Value 77.97% ; FCFF base≈111.4m ; Y1≈127.7m ; Y5≈187.9m
[DCF] Fair Price = 1.59 (EV 2.83b - Net Debt 2.55b = Equity 279.2m / Shares 175.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: -86.06 | Revenue CAGR: -4.82% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.06 | Chg30d=+187.16% | Revisions=+69% | Analysts=12
EPS next Quarter (2026-09-30): EPS=0.08 | Chg30d=N/A | Revisions=+69% | Analysts=13
EPS current Year (2026-12-31): EPS=-0.19 | Chg30d=+62.64% | Revisions=+69% | GrowthEPS=+73.3% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=0.21 | Chg30d=+61.76% | Revisions=+56% | GrowthEPS=+214.1% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +69%